In this Between The Dose bonus episode of The Elevated Dose, I break down the new World Health Organization (WHO) guidelines on GLP-1 medications for obesity and what they mean for people actively using or considering GLP-1 therapy.

This episode explains, in plain language, how the WHO now formally recognizes obesity as a chronic, relapsing disease and endorses GLP-1 receptor agonists as legitimate long-term medical treatment for obesity, not shortcuts or failures of willpower.

We cover:

• ​ What the WHO guidelines actually say about GLP-1 medications for obesity
• ​ Why obesity is now classified as a chronic disease requiring ongoing care
• ​ How GLP-1 drugs like semaglutide and tirzepatide fit into long-term obesity treatment
• ​ Why weight regain after stopping GLP-1 medication is expected biology, not personal failure
• ​ The role of structure, routine, and behavioral support alongside GLP-1 therapy
• ​ The real barriers to GLP-1 access, including cost, insurance, and health-system limitations
• ​ What these guidelines mean for plateaus, slow progress, maintenance, and medication changes

This episode is especially relevant if you are:

• ​ On a GLP-1 and feeling stalled or discouraged
• ​ Navigating maintenance or worried about weight regain
• ​ Considering starting a GLP-1 medication for obesity
• ​ Recovering from years of dieting, medical gaslighting, or shame-based weight loss care

The WHO guidance validates what many people on GLP-1s already know from lived experience: obesity treatment is not about willpower; it’s about biology, access, and sustained medical support.

This episode is educational and based on lived experience. It is not medical advice. Always consult your healthcare provider regarding GLP-1 medications and obesity treatment.

Stay up to date on all things The Elevated Dose at www.theelevateddose.com

What happens after the weight loss works?

In this episode I dive into the part of GLP-1 care no one really prepares you for, the long game. The quiet exhaustion that can show up after success. The identity shift that happens when the urgency fades. And the emotional weight of realizing this isn’t a phase, a reset, or a short-term solution.

This conversation isn’t about side effects or starting a GLP-1. It’s about what comes next.

If you’ve been on a GLP-1 long enough for the excitement to wear off and you’re feeling tired even though things are “working”, this episode will help you understand why.

In this episode, we talk about:

• ​What journey fatigue really is (and what it isn’t)
• ​Why exhaustion often shows up after success
• ​The emotional reality of long-term GLP-1 care
• ​Maintenance anxiety and the fear of “messing it up”
• ​Identity shifts after weight loss
• ​Why gratitude and exhaustion can coexist
• ​Letting go of urgency and learning to live inside stability
• ​Why this isn’t a phase it’s care

Resources & Support

• ​Explore GLP-1 care and long-term provider support with Fridays: https://www.joinfridays.com/?via=carrie

Use code DOSE to save on your first month.

Stay Connected

Follow The Elevated Dose for grounded conversations about metabolic health, GLP-1 care, maintenance, and life beyond the scale.

Subscribe and leave a review if this episode resonated, it helps more people quietly navigating this phase find the show.

Share this episode with someone who did everything right… and is still tired.

Follow for more across social media at www.theelevateddose.com

This isn’t a phase.

It’s the long game.

If you’re on a GLP-1 and not getting the results everyone else is talking about, this episode is for you.

Today we’re breaking down the future of obesity and metabolic care: NuSH (nutrient-stimulated hormone therapy) and OMM (obesity management medications) the next era of treatment for chronic obesity and metabolic health.

I walk through my own story of being a true “non-responder” to Ozempic and Trulicity, and how everything changed when I finally found the right mechanism with Mounjaro. And then we zoom out into what’s coming next: multi-hormone therapies, triple agonists, amylin-based options, oral OMM meds, and the new brain-targeted treatments designed to help people whose bodies simply didn’t click with current medications.

We also talk about the real-world side of all this; insurance cuts, AI-driven prior auth denials, employer carve-outs, compounding, telehealth access, and the shift toward treating obesity as a true chronic metabolic disease.

If you’re feeling discouraged, stuck, or scared your medication isn’t working… you are not broken. You might just be early in the story. And the next chapter of GLP-1 and OMM care is being built for people exactly like you.

Start with Fridays (my telehealth partner):

👉 https://www.joinfridays.com/?via=carrie

Explore GLP-1 with licensed U.S. providers: no insurance required, transparent pricing, and real medical care without judgment. If you're listening before December 4th you can use code DOSEBF to take advantage of the Cyber Monday special or after that code DOSE will still give you a savings.

Access all my resources in one place:

👉 https://beacons.ai/theelevateddose

GLP-1 info, Custom GPT's, my favorite products, Substack, Facebook group, and more.

Subscribe on Substack for deep-dives & weekly education:

👉 https://theelevateddose.substack.com